Compare GSK plc (GSK) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hasbro, Inc. — how do they compare? GSK plc trades at $52.76 (market cap $101.34B), while Hasbro, Inc. trades at $81.48 (market cap $11.39B). The key difference: GSK plc is far larger — about 8.9× Hasbro, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | HAS | |
|---|---|---|
Market Cap | $101.34B | $11.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $105.88 |
52-Week Low | $36.20 | $70.95 |
Enterprise Value | $121.95B | $13.66B |
Dividend Yield | 3.49% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Hasbro (HAS) trades at $78.42, down 1.4% on the day, with technical indicators showing a bearish trend while fundamentals reveal mixed signals. The company reported a net loss of $322.4M in 2025 despite beating earnings expectations for three consecutive quarters, with revenue of $4.7B and negative profit margins. Analyst consensus remains strongly positive with a $105.43 price target and no sell ratings among 33 analysts, though technical signals and recent stock performance suggest near-term pressure.
The investment case hinges on execution of Hasbro's 'aging up' strategy and Wizards segment growth against significant debt levels and profitability challenges. While Wall Street sees 34% upside to consensus targets, investors face risks from competitive pressures, high valuation multiples, and inconsistent earnings performance that could limit near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
